Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
22 mars 2021 16h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Announces Pricing of Public Offering
16 févr. 2021 06h45 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
04 sept. 2019 08h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
03 sept. 2019 16h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
14 août 2019 08h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
07 août 2019 13h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta
31 juil. 2019 09h20 HE
|
Hepion Pharmaceuticals, Inc.
- Accelerating NASH Research Programs - EDISON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of...
Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
29 juil. 2019 16h15 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”
22 juil. 2019 14h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH
27 juin 2019 08h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...